Purpose: To describe the clinical findings and mutations in affected members of two families with an autosomal recessive retinal dystrophy associated with mutations in the protocadherin-21 (PCDH21) gene. Methods: A full genome scan of members of two consanguineous families segregating an autosomal recessive retinal dystrophy was performed and regions identical by descent identified. Positional candidate genes were identified and sequenced. All patients had a detailed ophthalmic examination, including electroretinography and retinal imaging.
Retinitis pigmentosa (RP) is a genetically determined disorder in which there is progressive dysfunction and degeneration of the rod and cone photoreceptors. Inheritance may be autosomal dominant, autosomal recessive, and Xlinked recessive, and even among these genetic subtypes there is considerable genetic heterogeneity. Most progress has been made in identifying genes causing autosomal dominant and X-linked disease (RetNet). In recessive RP, current genes account for only 50% of families in which retinal disease is the only manifestation [1] .
As part of a larger study investigating the genetic causes of RP and early onset retinal dystrophies, we used autozygosity mapping in two consanguineous families with autosomal recessive Retinitis Pigmentosa (arRP)to identify a common autozygous region on chromosome 10q. We subsequently identified null mutations in protocadherin-21 (PCDH21), a photoreceptor-specific gene [2, 3] , as the cause of the retinal disease in these families.
generation consanguineous family of Middle-Eastern descent with 4 affected (2 male and 2 female) and two unaffected siblings. The affected individuals ranged in age from 32 to 42 years. The second (family 2) was a consanguineous family of South Asian descent with one affected male individual and three unaffected siblings. Informed consent was obtained from all study participants, and the study conformed to the tenets of the Declaration of Helsinki. Two 10 ml EDTA tubes of peripheral venous blood were drawn from all available family members, including both affected and unaffected individuals, and samples were frozen. DNA was extracted using the Nucleon™ BACC-2 genomic DNA kit (GE Healthcare Life Sciences, Buckinghamshire, UK). Following cell lysis, deproteinization was performed using sodium perchlorate. DNA extraction was achieved with chloroform and Nucleon™ resin before DNA recovery and washing. DNA analysis: Genome-wide linkage scans were performed to identify regions of autozygosity (where both alleles are identical by descent and are copies of a common ancestral gene). DNA samples from all affected family members were genotyped using the Affymetrix human GeneChip® Mapping Array (version Xba142 2.0) for family 1 and the GeneChip® Human Mapping 100 K set array for family 2 (Affymetrix, Santa Clara, CA). The detailed methodology for genotyping using the GeneChip® array has been previously described [4] . Briefly, 250 ng of genomic DNA was digested with XbaI (New England Biolabs, Ipswich, MA) for 2 h at 37 °C, ligated with XbaI adaptors using T4 DNA ligase (New England Biolabs). The ligation reaction was diluted in 1:4 (vol/vol) with molecular grade water (Sigma-Aldrich, St. Louis, MO) to 100 µl. Ten µl of the diluted ligation mix was used to setup selection by PCR (Fragment Selection by PCR) in triplicates. The pooled PCR products were purified using QIAGEN MinElute 96 UF plate (Qiagen, Duesseldorf, Germany). The concentration of PCR products was quantified using ND-1000 Nanodrop spectrometry (Thermo Fisher Scientific, Waltham, MA). Purified PCR product (90 ng) was fragmented with 0.25 units DNaseI ('Fragmentation Reagent'; Affymetrix), labeled with 'Labeling Regent' (Affymetrix). The labeling reaction (70 µl) was mixed with 190 μl hybridization reagent and denatured at 99 °C for 10 min (all as detailed in the Affymetrix GeneChip Mapping 100K Assay Manual). Finally the denatured hybridization mixture was injected into Affymetrix Human Mapping XbaI chips and incubated at 48 °C for 16 h, followed by automatic washing and staining in a Fluidics Station 450, and scanned by using the GeneChip® Scanner 3000 7G (Affymetrix). Primers for direct sequencing were as described by Bolz et al. [5] . PCR amplification was performed using a 20-µl reaction mix, including Abgene Reddymix with or without dye (AB795, AB793; Abgene, Epsom, UK). Ten microliters of Reddymix was combined with 5 µl of deionized water, 2 µl (10 pmol) of forward and reverse primer, and 1 µl (50-100 ng) of genomic DNA. All exons were optimized and amplified at 55 °C. DNA fragments were purified using Montage PCR cleanup plates, according to the standard protocol (Millipore, Watford, UK). PCR cleanup (purple plates) was performed using 15 μl of PCR product made up to 100 μl with deionized water (ddH2O) and transferred to the purple plates. Ten min of vacuum was applied to the plates until the wells were empty. Twenty five μl of ddH2O was added to each well and a further 3 min vacuum was applied. Twenty μl of ddH2O was added to each well; the plate covered and vortexed at 1,000 rpm for 10 min. The remaining contents of each well (clean PCR product) was then transferred for storage. The Big Dye terminator cycle sequencing reaction was then performed using a 10-µl reaction mixture containing 0.5 µl of BigDye v3.1 Applied Biosystems™ (ABI Ltd, Warrington, Cheshire. UK), 2 µl of PCR product, 1.5 µl of 5 picomolar (pM) forward or reverse primer, 3.5 µl of ddH2O, and 2.5 µl of sequencing buffer (ABI Ltd) containing 5x TrisHCl and MgCl2. The sequencing reaction mixture was purified using the Montage sequence cleanup plate (Millipore, Watford, UK): 25 μl of injection solution (Millipore,) were added to each well, and the total 35 μl was transferred to the blue plate and vacuumed for 3 min. A further 25 μl of injection solution was added to each well and vacuumed again for 4 min. Twenty five μl of injection solution was again added to each well, the plate covered and vortexed for 10 min. The remaining volume was transferred to the sequencing plate and run on the ABI 3700 sequencer. The DNA sequence was analyzed using DNAStar® Inc. (Madison, WI). To check segregation of the mutant alleles with disease, restriction digests were performed. Family 1 was investigated using HaeIII enzyme (Figure 2 ; New England Biolabs Ltd, NEB, Hitchin, Herts, UK), while in family 2 a digest using an E. coli strain that carries the BglI gene from Bacillus globigii (BglI [NEB]) was performed. One unit (0.2 μl) of enzyme was combined with 2 μl of 1x NEBuffer 3 (NEB, Herts, UK), 10 μl of PCR product and brought to a 20 μl reaction volume with deionized H2O (ddH2O) and digested for 16 h at 37 °C. Heat inactivation was performed at 80 °C for 20 min and the product run out on a 5% agarose gel.
Clinical examination: Affected individuals underwent a full clinical examination, including Logarithm of the Minimum Angle of Resolution (LogMAR) visual acuity, color vision testing using the Ishihara plates, refraction, slit-lamp biomicroscopy, Goldmann visual field testing, and color fundus photography. A subset of patients underwent Figure 1 . The pedigrees of the two families that took part in the study (denoted family 1 and 2 in the text) are displayed. Open and closed symbols denote unaffected and affected individuals, respectively. Deceased family members are denoted by diagonal lines; arrows indicate the probands in each family. A horizontal double line between parents indicates consanguinity. Panel A is a pedigree drawing of family 1, a first cousin consanguineous middle-eastern family, with four affected siblings. Panel B shows the nuclear family who took part in the study, and is part of a larger consanguineous pedigree not displayed or available for the study; the parents illustrated are first cousins. electroretinography using International Society for Clinical Electrophysiology of Vision (ISCEV) protocols [6, 7] .
RESULTS
In family I, analysis of the data from the Affymetrix gene chip array revealed a region of 47 contiguous homozygous single nucleotide polymorphisms (SNPs) on chromosome 10q23.1-23.3 spanning an interval of 10 cM in all four affected individuals. The parents and two unaffected siblings were heterozygous for these SNPs. This was the only significant region where affected individuals were homozygous and unaffected family members were not. The region contained approximately 45 genes of which four, PCDH21 (OMIM 609502); LRRC21 (leucine-rich repeat-containing protein 21 precursor, retina-specific protein photoreceptor-associated LRR superfamily [8] ); RGR (retinal pigment epithelium [RPE]-retinal G protein-coupled receptor -OMIM 600342), and OPN4 (melanopsin -OMIM 606665), were highly expressed in the retina relative to other human tissues (NCBI).
Direct sequencing of the coding regions and intron-exon boundaries of LRRC21 and RGR showed no variants in affected individuals. Sequencing of the 17 coding exons of PCDH21 showed a homozygous single base deletion within exon 4, c.338delG p.G113AfsX1 (Figure 2A ). The mutation segregated as a recessive allele in the family (Figure 3 ) and was not detected in 292 control chromosomes (86 UK blood donors, European Collection of Cell Cultures (ECACC) and 60 ethnically matched control individuals). In addition, the specific change was not found in a panel of DNA from 192 arRP and 96 Leber congenital amaurosis (LCA) patients recruited from Moorfields Eye Hospital (London, UK).
In family 2, the largest region of autozygosity, which contained 195 contiguous homozygous SNPs, was on chromosome 10q. Direct sequencing of PCDH21 revealed a homozygous single-base deletion in exon 13, c.1459delG, p.G487GfsX20 ( Figure 2B ). This is predicted to lead to truncation of the protein through a premature stop codon, 19 codons downstream of the deletion. This deletion segregated as a recessive allele in family 2 and was not found in 292 control chromosomes or in our LCA and arRP panel. Both deletions reside within the cadherin domains of the protein and occur at amino-acid positions that are highly conserved across species (Figure 4A-D) .
The clinical history and phenotype in affected members of both families was similar. In family 1, nyctalopia was first reported in late teenage years, and photophobia occurred in the mid-twenties. The visual acuity was 0.1 (LogMAR) in the early 30s, deteriorating to "hand movements" by the early 40s. All affected family members had a severe color vision defect, and all had a low myopic refractive error. Fundus examination revealed vessel attenuation, diffuse retinal pigment epithelial changes, and sparse bone spicule pigment migration in the retinal periphery in the younger patients. With disease progression, there was dense pigment migration and atrophy both at the macula and in the periphery (Figure 5A-D) . Electroretinography (ERG) in the three oldest affected individuals (age 42, 40, 34) showed both rod and cone responses; the ERG in the youngest affected family member, age 32 years (IV6), showed a cone-rod pattern of disease.
Only one affected individual in family 2 was available for examination. He had onset of symptomatic night blindness at 18 years of age. When examined at 30, his visual acuity was 0.2 LogMAR in each eye, but this had declined to 1.5 LogMAR in each eye at the age of 44 years and hand movements (HM) by the age of 46 years. His refraction measured −5 diopters spherical equivalent. Color vision was very abnormal at his initial examination. His fundus findings were of early RPE depigmentation at the macula at age 32 years. Later there were circular patches of pigment epithelial atrophy both at the macula and in the periphery associated with pigment migration and vessel attenuation ( Figure 5E ). Goldmann visual field testing at 46 years of age revealed residual peripheral islands of vision to the largest and brightest targets (V4e and III4e; see Figure 5F ). The ERG at age 34 years revealed no detectable rod or cone responses in either eye.
DISCUSSION
PCDH21 is photoreceptor-specific cadherin involved in the assembly of outer segment discs [2] . The protein is present at the base of the developing outer segment and co-localizes with Prominin 1 -a gene encoding a pentaspan transmembrane glycoprotein (PROM1). Both proteins are involved in disc morphogenesis [9] . Mutations in PROM1 have been implicated in autosomal dominant cone rod dystrophy and arRP [10, 11] . Yang et al. [9] postulated that PCDH21, PROM1, and cytoskeletal actin are responsible for the formation of nascent discs at the base of the outer segment model whereby new disc membranes form by an evagination of the ciliary plasma membrane followed by rim growth. In contrast to the pcdh2 −/− mice generated by Rattner et al. [2] in which the outer segments were shortened, fragmented, and degenerate, the mutant prom1 (R373C) transgenic mice have stacks of disc membranes that were of excessive size and aligned perpendicular to normal disc orientation.
PCDH21 is a good candidate for human inherited retinal degenerations, and Bolz et al. [5] screened a large number of arRP, LCA, and Usher syndrome type 1 patients; three heterozygous variants were described but none that were shown to be definitely disease associated. Our study provides evidence that PCDH21 is a rare cause of nonsyndromic RP.
The retinal phenotype is consistent in the two families with night vision loss in the late teenage years but relatively well preserved central vision until the late 30s. In the early 40s vision deteriorates markedly. There are characteristic circular patches of pigment epithelial atrophy both at the macula and in the periphery appearing late in the disease process. This atrophy of the RPE and inner choroid occurring together with photoreceptor dysfunction suggest that phagocytosis of abnormal outer segments of the mutant retina might have a toxic effect on the RPE. All affected individuals examined had severe color vision defects, and ERGs performed at the referring institution (family 1) and at our institution (family 2) revealed severe cone and rod degeneration; the youngest affected individual had a cone-rod pattern of disease, suggesting that the earliest manifestation of mutations in PCDH21is a cone-rod dystrophy.
In summary, we have identified two consanguineous families who have separate, novel, homozygous, frameshifting deletions that result in stop mutations that would be expected to abrogate protein function and cause nonsensemediated decay [12] of the transcribed RNA. The phenotype is of a retinal dystrophy that begins in late teenage years with nyctalopia and visual field defects and by the fourth decade results in significantly impaired central vision.
